Clinical Research Directory
Browse clinical research sites, groups, and studies.
Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction
Sponsor: Samsung Medical Center
Summary
This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) and being treated with dual antiplatelet therapy (DAPT).
Official title: Routine Use of Potassium Competitive Acid Blocker Versus Guideline-Directed Gastrointestinal Protection Strategy in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy: A Randomized Trial
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
5000
Start Date
2026-04-01
Completion Date
2030-12-31
Last Updated
2026-03-12
Healthy Volunteers
No
Interventions
Zastaprazan
Zastaprazan citrate 20mg will be administered orally once daily for gastrointestinal protection according to the study protocol.
Proton Pump Inhibitors (PPI)
Guideline-directed gastrointestinal protection using various proton pump inhibitors as determined by the physician.